Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Top Cited Papers
- 5 February 2009
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (6) , 626-633
- https://doi.org/10.1056/nejmhpr0807774
Abstract
During the past decade, the price of cancer drugs and the spending for cancer treatments by Medicare have increased dramatically. The author outlines the usual tools Medicare uses to control its spending on drugs and discusses the policies that make cancer drugs a special case and prohibit the regulation of their prices and utilization.Keywords
This publication has 28 references indexed in Scilit:
- Tier 4 Drugs and the Fraying of the Social CompactNew England Journal of Medicine, 2008
- Costs of Cancer Care: A View From the Centers for Medicare & Medicaid ServicesJournal of Clinical Oncology, 2007
- Cost of Cancer Care: Issues and ImplicationsJournal of Clinical Oncology, 2007
- Economics of New Oncology Drug DevelopmentJournal of Clinical Oncology, 2007
- Fundamental Reform of Payment for Adult Primary Care: Comprehensive Payment for Comprehensive CareJournal of General Internal Medicine, 2007
- Chemotherapy and the war on cancerNature Reviews Cancer, 2005
- Reference Pricing For Drugs: Is It Compatible With U.S. Health Care?Health Affairs, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- The Effect of Prospective Payment on Medicare ExpendituresNew England Journal of Medicine, 1989